Drugs / LBH581
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01222936 | May 2008 → Jun 2009 | small cell lung carcinoma | Southern Europe New Drug Organization | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LBH581 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01222936 ↗ |
| Action | Inhibit | “histone deacetylase (HDAC) inhibitor” NCT01222936 ↗ |
| Route | Intravenous | “given as a 30 minutes infusion at the dose of 20 mg/m2 i.v.” NCT01222936 ↗ |